Thursday, 24 November 2022

Validated Stability Indicating Rp-Hplc and Hptlc Methods for the Determination of Zanamivir in Bulk and Pharmaceutical Formulation| Chapter 9 | Challenges and Advances in Pharmaceutical Research Vol. 9

 The objective of the work is to develop a natural, precise, correct, validated stability signifying RP-HPLC and HPTLC method for the determination of Zanamivir all-inclusive and capsule dosage form. The HPLC break-up was achieved on Agilent TC C18 (2) 250 x 4.6 mm, 5 μ column utilizing mobile phase arrangement of methanol - 0.02 M phosphate safeguard, pH 5, 50:50 (V/V). The flow rate was kept constant at 1 ml/brief time period at room temperature. At 230 nm, UV discovery was used to quantify. Zanamivir had a memory time of 3.6 minutes. The result got with the detector reaction was found expected linear in the concentration range of 2-12 μg/ml. The system employed TLC aluminium plates precoated with silica coagulate 60F-254 as the stationary chapter. The solvent system involved Chloroform: methanol: acetic acid (4.5:0.5:0.3v/v) and before scanned .The system was found to present compact spot for Zanamivir (Rf value of 0.29 ± 0.02). The undeviating regression analysis dossier for the calibration plots showed good friendship with r2=0.9999 ± 0.0001 in the aggregation range 500-3000 ng/spot. The linearity, range, precision, veracity, detection, and quantitation limitations of the submitted techniques, in addition to their analytical performance, were statistically ratified. The suggested methods commit successfully separate Zanamivir from allure degradation products when it was bear hardship various stress settings; suitable way, they were regarded as active stability-indicating methods. It is concluded that this technique maybe used for zanamivir portion of drug or other consumable forms and bulk drug routine quality control.

Author(s) Details:

C. H. Bhirud,
PRES’S College of Pharmacy (For Women), Chincholi, Nashik, India.

Please see the link here: https://stm.bookpi.org/CAPR-V9/article/view/8679

No comments:

Post a Comment